Bosnia and Herzegovina
Global Fund’s new HIV and TB multicountry grants in Eastern Europe and Central Asia begin implementation
The Global Fund Board has recently approved several multicountry grants, whose aim is to address priorities “deemed critical to fulfil the aims of the Global Fund 2017-2022 strategy,” and to address needs that are not being fulfilled by national (single country) allocations.
Significant impacts exist as a result of Global Fund withdrawal from programs and service delivery in Bosnia and Herzegovina
Bosnia and Herzegovina- BiH, an upper-middle income country with low HIV prevalence rates in both the general and high-risk populations, estimated at around <0.1% and <0.5% respectively, became ineligible for Global Fund support after September 2016. In the country, possession of drugs and organization of provision of sex services are criminalized.
Additional information on the decision not to approve extensions for HIV and TB grants to Bosnia and Hercegovina
In GFO #293, we reported that the Global Fund Board turned down a recommendation to provide additional funding for a TB grant and an HIV grant in Bosnia and Herzegovina. Although to still do now know why the Board decided not to grant the additional funding, we now have additional information on what was being requested and why. As well, we are able to report on the reaction of the principal recipient (PR), UNDP.
GFO has learned that the Global Fund Board has turned down a recommendation to provide additional funding for a TB grant and an HIV grant in Bosnia and Herzegovina.
There has been no public announcement of the Board decision. Nor has the Global Fund made public any details concerning the amounts involved, the rationale for the recommendation, or the reasons why the recommendation was not approved.
Bosnia and Herzegovina (BiH) will from December 2015 no longer be eligible for Global Fund financing as it is currently designated an upper middle-income country with low burden of disease.
The Global Fund Board has approved Phase 2 funding for a Round 9 HIV grant in Bosnia and Hercegovina in the amount of $13.5 million. The principal recipient (PR) for the grant is the United Nations Development Programme (UNDP). UNDP is also PR for another HIV grant, which has been essentially completed, and for a TB grant in Bosnia and Hercegovina.